Scribe Therapeutics (NASDAQ:SCTX) Releases Earnings Results, Beats Estimates By $2.36 EPS

Scribe Therapeutics (NASDAQ:SCTX) issued its quarterly earnings results on Wednesday. The company reported ($3.84) EPS for the quarter, topping analysts’ consensus estimates of ($6.20) by $2.36, Zacks reports.

Scribe Therapeutics Trading Up 6.6%

Shares of NASDAQ:SCTX opened at $30.90 on Thursday. Scribe Therapeutics has a one year low of $17.31 and a one year high of $39.60.

Key Stories Impacting Scribe Therapeutics

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: Scribe Therapeutics reported a second-quarter loss of $3.84 per share, substantially narrower than the $6.20 consensus estimate. Management also highlighted progress across its cardiovascular pipeline, including the launch of a first-in-human Phase 1 trial for STX-1150, an experimental therapy designed to produce long-lasting LDL cholesterol reduction without permanent genetic changes. Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
• Positive Sentiment: The company received more than $25 million from the California Institute for Regenerative Medicine to advance STX-1200 for Lp(a) reduction and STX-1400 for triglyceride reduction toward clinical testing. Scribe also raised approximately $155.5 million through an upsized IPO and a concurrent private placement with Sanofi, leaving it funded into the first half of 2029. Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
• Positive Sentiment: HC Wainwright began coverage with a “Buy” rating and a $60 price target, well above the company’s recent trading level. The firm forecasts continued losses but expects fiscal 2026 and fiscal 2027 losses of $6.72 and $4.90 per share, respectively. HC Wainwright Begins Coverage on Scribe Therapeutics
• Neutral Sentiment: Zacks Research upgraded SCTX to “Hold,” indicating a more balanced view of the shares following the recent developments. Management is also scheduled to participate in upcoming healthcare investor conferences, which could provide additional visibility into its programs. Scribe Therapeutics to Participate in Upcoming Investor Conferences
• Negative Sentiment: Scribe remains unprofitable, and the capital raise increased the share count, creating potential dilution for existing investors. The company’s valuation also remains dependent on successful clinical trials and future regulatory approvals.

Analyst Upgrades and Downgrades

SCTX has been the subject of several recent analyst reports. Guggenheim began coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $50.00 price objective for the company. HC Wainwright began coverage on shares of Scribe Therapeutics in a report on Monday. They issued a “buy” rating and a $60.00 target price on the stock. Wells Fargo & Company assumed coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They issued an “overweight” rating and a $60.00 target price for the company. Wall Street Zen raised shares of Scribe Therapeutics to a “hold” rating in a report on Saturday, August 1st. Finally, Leerink Partners began coverage on shares of Scribe Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price target on the stock. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.75.

Insider Activity at Scribe Therapeutics

In related news, Director Behzad Aghazadeh bought 7,905 shares of the firm’s stock in a transaction on Tuesday, July 28th. The shares were purchased at an average price of $18.25 per share, with a total value of $144,266.25. Following the completion of the purchase, the director owned 3,088,888 shares in the company, valued at $56,372,206. This represents a 0.26% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Bio Fund Ii L.P. Ah purchased 333,333 shares of the stock in a transaction dated Monday, July 27th. The shares were bought at an average price of $15.00 per share, with a total value of $4,999,995.00. Following the completion of the acquisition, the insider directly owned 2,385,075 shares of the company’s stock, valued at approximately $35,776,125. This represents a 16.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 3,727,237 shares of company stock worth $56,291,746.

Scribe Therapeutics Company Profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.